

# Epigenetic Age Advancement is Associated with Lower CD4 T-cell Count, Increased Mortality Risk, and Frailty in Older Adults with HIV

Carrie Johnston, MD, MS<sup>1</sup>, Alina Pang, PhD<sup>1</sup>, Eugenia Siegler, MD<sup>2</sup>, Chelsie O Burchett MA<sup>2</sup>, Charlene Thomas MS<sup>3</sup>, Lishomwa Ndhlovu MD, PhD<sup>1</sup>, Marshall J. Glesby, MD, PhD<sup>1</sup>, Michael J. Corley, PhD<sup>1</sup>

<sup>1</sup>Weill Cornell Medicine, Division of Infectious Diseases New York, NY, USA

<sup>2</sup>Weill Cornell Medicine, Division of Infectious Diseases New York, NY, USA

<sup>3</sup>Weill Cornell Medicine, CTSC Biostatistics Core New York, NY, USA

## BACKGROUND

With advancements in antiretroviral therapy, people with HIV (PWH) are living longer lives and often aging into geriatric care. PWH are more likely to experience medical co-morbidities and geriatric syndromes including frailty as they age.

- Epigenetic changes to DNA by different patterns of methylation have been associated with aging
- People with HIV have been demonstrated to have advancement of epigenetic-based age calculation compared to chronologic age<sup>1</sup>
- Specific patterns of DNA methylation have been associated with an epigenetic frailty score<sup>2</sup>

**We aimed to investigate the association between epigenetic aging and phenotypic measures of frailty, as well as epigenetic methylation signatures associated with frailty, in older PWH.**

## METHODS


### Recruitment:

- Older adults (55 years and older) with HIV were recruited from the outpatient HIV clinical practice at NYPH-WCM using an age-stratified random selection strategy.

### Procedures:

Study Participants (N=164)  
Completed a study visit in the CTSC

Of those, 158 provided a blood spot for epigenetic analysis



### Analysis:

- Genome-wide DNA methylation was measured from dried blood spots using the Illumina MethylationEPIC platform and analyzed using 6 established epigenetic age algorithms including DNAm PhenoAge.
- The epigenetic frailty risk score (eFRS) was calculated based on characteristic methylation loci<sup>2</sup>.

### Study Population:

Characteristic	N(%) or Median (IQR)
Age (years)	60 (56-64)
Female sex	52 (33%)
Self-Identified Race	
- Black	76 (50%)
- White	47 (31%)
- Other	30 (19%)
CD4 T-cell Count (cells/ml)	588 (323-811)
Veterans Aging Cohort Study (VACS) Mortality Index	28 (18-43)
PhenoAge	66 (62-71)
Epigenetic Age Advancement <sup>†</sup>	5.4 (SD 6.6)
eFRS Frailty Score	0.09 (0.06-0.12)
Fried Frailty Category <sup>‡</sup>	
- Nonfrail	49 (33%)
- Prefrail	84 (56%)
- Frail	16 (11%)


<sup>†</sup>Veterans Aging Cohort Study (VACS) Index of 28 correlates to a 10.8% risk of all-cause 5 year mortality.

<sup>‡</sup> Epigenetic Age Advancement defined as PhenoAge - Chronologic Age


<sup>‡</sup> Frailty data missing/incomplete for 8 participants.

## RESULTS:

**Epigenetic Age Advancement is associated with younger age, lower CD4 T-Cell Count and higher VACS Index in Older Adults with HIV**



### Epigenetic Age Advancement Related to Frailty Status



- Epigenetic age advancement was related to epigenetic frailty risk score in a univariate logistic regression model (B coefficient 57.6 [95%CI: 34.9-80.2])

## CONCLUSIONS

- In this study of older adults with HIV, the average epigenetic age advancement (EAA) was 5.4 years, as calculated by PhenoAge.
- EAA was associated with lower CD4 T-cell counts and higher VACS indices.
- In a model that included age, sex and race, EAA was also associated with an epigenetic frailty risk score and frailty phenotype

**These results suggest epigenetic clocks are a valuable biomarker of aging-related pathologies including frailty and mortality risk, and warrant further study.**

## ADDITIONAL INFORMATION

Author Contact: Carrie Johnston, MD, MS

[cmd9008@med.cornell.edu](mailto:cmd9008@med.cornell.edu)



## ACKNOWLEDGEMENTS

Study Participants, Weill Cornell CTSC, Biostatistics Core



## FUNDING

National Institute of Aging (K23 AG 072960)

National Center For Advancing Translational Sciences (UL1TR000457)

National Institute of Mental Health (R21 MH115821)

National Institute of Neurological Disorders and Stroke ( R01 NS117458)

## REFERENCES

1. Horvath, S. and Levine, A.J., 2015. The Journal of infectious diseases, 212(10), pp.1563-1573.
2. Li, Xiangwei, et al. *Nature Communications* 13.1 (2022): 5269.